Skip to main content

Changes to our National Precertification List (NPL)


Important NPL update

Effective September 1, 2019, precertification is required for the following: 

  • Cervical laminoplasty
  • Aveed® (testosterone undecanoate)

 

The following new-to-market drugs require precertification:

  • UdenycaTM (pegfilgrastim-cbqv) — precertification effective March 1, 2019. This drug is included in the granulocyte colony-stimulating factor class.

  • Cablivi® (caplacizumab-yhdp) — precertification effective April 17, 2019.

  • Truxima® (rituximab-abbs) — precertification effective May 15, 2019. This drug is included in the immunologic agents class.

We encourage you to submit precertification requests at least two weeks before the scheduled services. 

To save time, request precertification electronically — it’s fast, secure and simple. Most precertification requests can be submitted electronically through the provider website or by using your Electronic Medical Record (EMR) system portal.

You can find more information about precertification under the General Information section of the NPL.